To examine whether abemaciclib altered CDK4 T172 phosphorylation we treated T47D breast cancer cells for 4 or 24 h with CDK4/6i and quantified CDK4 T172 phosphorylation by LC-MS/MS. This evidence concerns the gene CDK4 and breast carcinoma.